INSILICO Aktie

 

CAMBRIDGE, Mass., March 23, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the launch of PandaClaw, a transformative new feature of the PandaOmics engine that combines AI agents......

BOCA RATON, FL AND TORONTO, ONTARIO, March 16, 2026 (GLOBE NEWSWIRE) -- GNQ Insilico Inc. (“GNQ” or the “Company”), a corporation formed under the federal laws of Canada, and IB Acquisition Corp. (Nasdaq: IBAC) (“IBAC”), a Nevada special purpose acquisition company, today announced that they have entered into a definitive business combination agreement (the “BCA”) pursuant to which IBAC will acquire all of the issued and outstanding shares in the capital of GNQ by way of a statutory plan of arrangement under the Canada Business Corporations Act (the “Transaction”). Following closing of the Transaction, which is expected in the third quarter of 2026, the combined company expects to be publicly listed on Nasdaq. Shares will trade on Nasdaq under the symbol IBAC until the closing of the Transaction....

CAMBRIDGE, Mass., March 13, 2026 /PRNewswire/ -- Insilico Medicine (HKEX: 3696.HK, "Insilico" or the "Company"), a clinical-stage biotechnology company powered by generative artificial intelligence for drug discovery and development, today announced that it will report its financial......

CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia......

Hong Kong-listed Insilico Medicine has signed a cooperation agreement with the United Arab Emirates' drug regulator to advance the use of its artificial intelligence tools in drug discovery across the region, even as geopolitical tensions escalate in the Middle East. Shares of Insilico rose as much as 12.8 per cent in morning trading on Thursday before paring gains to close 8.6 per cent higher at HK$56.10. The advance outpaced the benchmark Hang Seng Index, which edged up 0.3 per cent. The......

Single 2.6B-parameter model achieves state-of-the-art performance across drug discovery benchmarks while running entirely on private pharmaceutical infrastructure CAMBRIDGE, Mass., March 3, 2026 /PRNewswire/ -- Insilico Medicine and Liquid AI today announced a partnership that creates......

The companies plan to jointly develop at least two research and development (R&D) programmes using Insilico Medicine's AI platform alongside CMS' expertise in clinical development. Under the agreement, The post Insilico and CMS launch drug discovery collaborations for CNS diseases appeared first on Pharmaceutical Business review....

CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico") (3696.HK), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology.......

NLRP3 is a validated anti-inflammatory target that mediates the release of proinflammatory cytokines IL-1β and IL-18, and ISM5059 targets systemic inflammatory conditions by targeting NLRP3 and blocking the inflammatory cascade at its source. Unlike ISM8969, Insilico's brain-penetrant......

Listed IPO INSILICO (03696.HK), which focuses on AI drug discovery, opened 4.56% higher this morning (3rd) before its gains expanded in the morning session, and peaked at $68.7, logging a new listing high. It last printed at $68.1, spiking 13.03%, with a trading volume of 1.5069 million shares, involving $100 million.Before the ......

The partnership will leverage Insilico's Pharma.AI platform for the development of small molecule inhibitors, with the agreement valued at nearly $120m. This agreement includes development and commercial milestone The post Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies appeared first on Pharmaceutical Business review....

Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...

Investigational New Drug (IND) approval from the U.S. Food and Drug Administration (FDA) paves the way for ISM8969 clinical study in the United States. The Phase I clinical trial aims to evaluate safety, tolerability, and pharmacokinetics profiles. ISM8969 is a novel oral therapeutic......

New "AI GYM for Science" dramatically boosts the biological and chemical intelligence of any causal or frontier LLM Up to 10x performance gains on key drug discovery benchmarks compared to LLMs that miss the mark on ~75–95% of tasks Advances Insilico's vision of Pharmaceutical......